Rob Pieters focuses on Acute lymphocytic leukemia, Immunology, Internal medicine, Leukemia and Cancer research. His Acute lymphocytic leukemia research is multidisciplinary, incorporating elements of Vincristine, Gene expression, Molecular biology and Acute leukemia. He has researched Immunology in several fields, including Chemotherapy and Drug resistance.
Internal medicine connects with themes related to Oncology in his study. His Leukemia study incorporates themes from Gene rearrangement, Chromosomal translocation, Myeloid, Pathology and Myeloid leukemia. His study on Cancer research also encompasses disciplines like
His primary areas of study are Internal medicine, Immunology, Cancer research, Leukemia and Oncology. His studies in Internal medicine integrate themes in fields like Gastroenterology and Endocrinology. His Immunology study typically links adjacent topics like Drug resistance.
His Leukemia research incorporates elements of Gene expression profiling, Myeloid, Molecular biology, Myeloid leukemia and microRNA. His Oncology research is multidisciplinary, relying on both Cancer, Cohort and Minimal residual disease. His research in Acute lymphocytic leukemia tackles topics such as Vincristine which are related to areas like Daunorubicin.
Rob Pieters mostly deals with Internal medicine, Oncology, Cancer research, Lymphoblastic Leukemia and Immunology. The Oncology study combines topics in areas such as Incidence, Single-nucleotide polymorphism, Survival analysis and Acute lymphocytic leukemia. His biological study spans a wide range of topics, including Haematopoiesis, Protein kinase B, Signal transduction, B cell and Leukemia.
His Leukemia study frequently intersects with other fields, such as Drug resistance. His Lymphoblastic Leukemia research incorporates themes from KMT2A and Pediatrics. His research investigates the connection between Minimal residual disease and topics such as Childhood Acute Lymphoblastic Leukemia that intersect with problems in Pharmacology.
Rob Pieters spends much of his time researching Internal medicine, Immunology, Cancer research, Leukemia and Hematology. Internal medicine and Oncology are commonly linked in his work. His Oncology research is multidisciplinary, incorporating perspectives in Cancer and White blood cell.
Rob Pieters combines subjects such as Fusion gene, Gene, B cell, Cladribine and Signal transduction with his study of Cancer research. Rob Pieters has included themes like Protein kinase B, Molecular biology, PI3K/AKT/mTOR pathway, PTEN and Drug resistance in his Leukemia study. His research on Hematology also deals with topics like
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
Monique L Den Boer;Marjon van Slegtenhorst;Renée X De Menezes;Renée X De Menezes;Meyling H Cheok.
Lancet Oncology (2009)
FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to γ-secretase inhibitors
Jennifer O'Neil;Jonathan Grim;Peter Strack;Sudhir Rao.
Journal of Experimental Medicine (2007)
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
Ching Hon Pui;Jun J. Yang;Stephen P. Hunger;Rob Pieters.
Journal of Clinical Oncology (2015)
Gene-Expression Patterns in Drug-Resistant Acute Lymphoblastic Leukemia Cells and Response to Treatment
Amy Holleman;Meyling H Cheok;Monique L den Boer;Wenjian Yang.
The New England Journal of Medicine (2004)
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial.
Rob Pieters;Martin Schrappe;Paola De Lorenzo;Ian Hann.
The Lancet (2007)
L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase
Rob Pieters;Stephen P. Hunger;Joachim Boos;Carmelo Rizzari.
Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance
Guo Wei;Guo Wei;David Twomey;David Twomey;Justin Lamb;Krysta Schlis.
Cancer Cell (2006)
Biological and therapeutic aspects of infant leukemia
Andrea Biondi;Giuseppe Cimino;Rob Pieters;Ching-Hon Pui.
Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification
Scott A Armstrong;Andrew L Kung;Andrew L Kung;Meghann E Mabon;Lewis B Silverman;Lewis B Silverman.
Cancer Cell (2003)
Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study.
Brian V. Balgobind;Susana C. Raimondi;Susana C. Raimondi;Jochen Harbott;Martin Zimmermann.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: